The investigators want to develop a gene expression profile for the prediction of immunotherapy response of patients with metastatic breast cancer presenting malignant pleural effusion.
1. The patiets with malignant pleural effusion are randomizned to be treated with cytokins(inteleukin 2) or dendritic cells(DC) plus cytokine induced killer cells(CIK) locally. 2. Malignant pleural effusion from metastatic breast cancer patient is obtained through thoracentesis and is centrifugalized to enrich cancer cells before the therapy. 3. The enriched cancer cells are flash frozen and stored at -80℃ until processing. 4. The gene expression in pleural effusion is detected by microarray to screen gene markers that are differently expressed between groups . 5. Statistical analysis is performed using unsupervised hierarchical cluster.
Study Type
OBSERVATIONAL
Enrollment
36
interleukin 2 2 million unit every week
Beijing Cancer Hospital
Beijing, China
immunotherapy response
Response of malignant pleural effusion to immunotherapy is evaluated with WHO guidelines
Time frame: 1 month
immunological status
compare the immunological status of pleural effusion before and after the therapy
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.